Rahul Winayak, Xinran Qi, Ali Moradi, Hedyeh Ebrahimi, Antonio Cruz Gomes, Miguel Zugman, Salvador Jaime-Casas, Xiaochen Li, Tanya B. Dorff, Joann Hsu, Alex Chehrazi-Raffle, Motomichi Takahashi, Kentaro Oka, Seiya Higashi, Peter P. Lee, Thomas P. Parks, Jennifer Karmouch, Robert R. Jenq, Sumanta Kumar Pal, Nazli Dizman. "Microbial dysbiosis as predictor of benefit from CBM588 as an adjunct to immune checkpoint blockade (ICB)–based first line therapies in metastatic renal cell carcinoma (mRCC).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.4519